Eap Osona Sud Alt Congost S.L.P. — Clinical Trial Site

26 Registered trials

2 Currently recruiting

Organisation

Eap Osona Sud Alt Congost S.L.P.

Location

Centelles, Spain

Identifier

ORG-100042732

Address

Placa Del Pla Del Mestre 7, 08540, Spain

Departments

#3420: Atención Primaria
Atencio a la Salut Sexual i Reproductiva – Medicina Familiar i Comunitaria
Centro de Atención Primaria
Department
Especialidades
family medicine
Family Phisician
General medicine
Infecciosas
Infectious Diseases Department
Internal medicine
Medicina Comunitària i de Família
Medicina Familiar y Comunitaria
Medicina interna
N/A
Pimary Care
Primary care
Servei de Medicina Comunitària i de Família
Unitat d’Investigació

Clinical trials at this site (26)

Search interface

MK-0616-013 Not authorised

2022-502777-42-00 Hypercholesterolemia 5
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
Clinical trial of molnupiravir (MK-4482) in adults who have COVID-19 and are not hospitalized, who are at high risk for serious illness from… Recruiting

2023-507227-36-00 SARS-CoV-2 (COVID-19) infection 5 2025-02-21
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
A clinical study of enlicitide in people with high cholesterol (MK-0616-037) Ended

2025-521495-54-00 Hyperlipidemia 5 2025-12-20
A study to test whether vicadrostat in combination with empagliflozin helps people with chronic kidney disease Ended

2024-518457-42-00 chronic kidney disease 4 2025-08-28
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening);… Ended

2024-519000-27-00 Hypertension 5 2025-07-17
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
Extension trial for adults with high cholesterol who completed a MK-0616 clinical trial Ended

2023-504922-20-00 Hypercholesterolemia 5 2024-08-23
An extension and crossover vaccination study on the immune response and safety of a vaccine against respiratory syncytial virus given to adu… Ended

2023-509762-38-00 Respiratory Syncytial Virus Infections 5 2024-08-01
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu… Ended

2022-502781-24-01 ASCVD - Atherosclerotic Cardiovascular Disease 5 2024-06-05
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A study on the long-term efficacy, safety and persistence of immune response of a vaccine against Herpes Zoster in older adults. Ended

2023-505255-51-00 Herpes Zoster 5 2022-08-08
Efficacy, immunogenicity, and safety of the 9vHPV vaccine in adult males 20 to 45 years of age Ended

2022-501974-21-00 Prevention of oral persistent infection caused by any o 5 2020-04-01
A study to assess and compare safety and tolerability of 3 months treatment with salbutamol administered via MDI containing propellant HFA-1… Ended

2023-509001-76-00 Asthma 5 2024-07-01
MK-0616-013 Ended

2022-502777-42-01 Hypercholesterolemia 5 2024-01-16
A Ph2 dose-finding study (MARS-17) to evaluate the efficacy and safety of GSK3858279 in adults with knee osteoarthritis pain. Ended

2022-502799-22-00 Knee osteoarthritis pain 4 2023-11-29
A Phase IIb/III, Double-Blind, Randomised, Active-Controlled, Multi-Center, Non-Inferiority Clinical Trial, to assess the safety and immunog… Ended

2023-508458-25-00 COVID-19 disease 10 2023-11-13
A double-blind, randomised, dose-finding trial to assess the efficacy, safety and pharmacokinetics of a single dose of albaconazole versus f… Ended

2023-504727-32-00 Acute vulvovaginal candidiasis 4 2023-09-18
A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with sea… Ended

2023-506189-29-00 SARS-CoV-2 and Influenza 4 2023-09-04
A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety, and reactogenicity of respirat… Ended

2022-501988-40-00 RSV-associated (subtypes A and B) disease in adults age 5 2023-08-17
Open-label, Multi-centre, Non-Inferiority study of safety and immunogenicity of BIMERVAX as heterologous booster for the prevention of coron… Ended

2023-504639-42-00 SARS-CoV-2 infection 4 2023-05-26
A study to evaluate the efficacy and safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 Ended

2023-504540-33-00 COVID-19 5 2023-03-06